Ulcerative Colitis Market

Ulcerative Colitis Market GLOBAL INDUSTRY INSIGHTS, TRENDS,
OUTLOOK, AND OPPORTUNITY ANALYSIS,
2016-2025
© Coherent market Insights. All Rights Reserved
Ulcerative Colitis Market Overview:
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The
inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among
people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other
indications are sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection
(sepsis), kidney stones and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as
colonoscopy, endoscopy, biopsy, CT scan and blood test.
If ulcerative colitis persists for over 8 years or longer, it may lead to colon cancer. The people having mild symptoms of this disease can be
cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates
are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps
prevent colon cancer.
Also, some genetically engineered drugs also used to treat ulcerative colitis. These drugs are made up of certain living organisms that help
suppress the inflammation, by targeting the inflammatory proteins such as cytokines. Some genetically engineered drugs approved by the
U.S. FDA for treatment of the condition are Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).
These genetically engineered drugs may show some side effects such as fever, headache, hives, low blood pressure, breathing difficulties,
back pain, and stomach pain. Also, these drugs may affect the immunity power of body to fight infection.
The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened
immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well
hydrated throughout the day, avoiding fatty foods, and limiting intake of high-fiber food.
© Coherent market Insights. All Rights Reserved
High prevalence in developed regions and increasing incidence rate in emerging economies will play major role
in driving growth of the ulcerative colitis market
According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is
most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed
are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising
incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies
will show high growth rate in incidence rate of ulcerative colitis in the near future.
According to data collected from various sources and compiled by Coherent Market Insights, Europe have the highest
annual rate of incidence worldwide, followed by North America and the lowest in Asia and Middle East.
However, North America holds the largest share in the global ulcerative colitis market due to continuous improvements in
drugs, increased uptake of medicines, awareness about treatment and increasing clinical research. APAC region will show
high growth in ulcerative colitis market during forecast years (2017-2024), due to raising awareness about the treatment,
changing lifestyle will cause to increase prevalence and incidence rate, entry of new drugs in the market also some
companies losing their patent of ulcerative drugs in coming years, like Humira (adalimumab) lost its patent in 2016 and
Remicade will lose its patent in 2018. Also, some drugs companies have launched their biosimilar drugs in ulcerative
colitis industry. For example, in 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand
name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.
Fill the form for an exclusive sample of this report :
https://www.coherentmarketinsights.com/insight/request-sample/238
© Coherent market Insights. All Rights Reserved
Some major companies playing leading role in ulcerative colitis market are :
AbbVie Inc.,
Hospira,
Celltrion Healthcare,
Johnson and Johnson,
F. Hoffmann-La Roche AG,
Warner Chilcott,
Janssen Pharmaceuticals Inc.
Takeda Pharmaceuticals Company Ltd.
Some leading drugs are used to reduce inflammation and swelling and to cure ulcerative colitis are
include :Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and
Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), Infliximab (Remicade).
Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/238
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting
organization focused on assisting its plethora of clients achieve transformational
growth by helping them make critical business decisions. We are headquartered in
India, with an office at the global financial capital in the U.S. Our client base
includes players from across all business verticals in over 150 countries worldwide.
We are uniquely positioned to help businesses around the globe deliver practical
and lasting results through various recommendations about operational
improvements, technologies, emerging market trends and new working methods.
We offer both customized and syndicated market research reports that help our
clients create visionary growth plans to provide traction to their business. We
meticulously study emerging trends across various industries at both the global
and regional levels to identify new opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
© Coherent market Insights. All Rights Reserved
SYNDICATED RESEARCH
COUNTRY SPECIFIC
STUDIES
ABOUT COHERENT MARKET INSIGHTS
Industries we cater
SECTOR COVERAGE
Healthcare
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
Chemicals & Materials
Bulk Chemicals
Advanced Materials
Speciality and Fine
Chemicals
Green Chemicals
Food Ingredients
© Coherent market Insights. All Rights Reserved
Cosmetic
Ingredients
Polymers &
Resins
ABOUT COHERENT MARKET INSIGHTS
KEY STATS
RESEARCH SOLUTIONS
FEASIBILITY
STUDIES
GLOBAL
REPORTS
100+
Insights Published Per Year
150+
Consulting Projects Till Date
125+
Clients Worldwide Per Year
110+
COUNTRY
ANALYSIS
CONSULT
PROJECTS
SURVEY
RESEAR
CH
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including
chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in
the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various
industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely
designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed
markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.
© Coherent market Insights. All Rights Reserved
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702
© Coherent market Insights. All Rights Reserved

Ulcerative colitis is the most common type of inflammatory bowel disease

Download Report